Healthcare
Live Price
Offline$1.23
+1.65% today
Window Change
-20.13%
Window
May 29, 2026 → Jun 18, 2026
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 15 bars · May 29, 2026 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Neuronetics, Inc. (STIM) is a Healthcare stock with a market cap of $140.00M and listed on NASDAQ. The stock last traded around $1.23 and down 20.1% across the available one-year price window (May 29, 2026 → Jun 18, 2026). Baseline metrics include revenue growth of +99.2%, EPS growth of +57.2%, a dividend yield of 0.0%. What stands out right now is revenue +99.2%, EPS +57.2%, free cash flow +34.8% with operating margin -21.1% and ROIC -27.0%. Valuation is more restrained than many high-expectation growth names at price/sales 0.9. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines STIM price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
STIM
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
STIM Max Drawdown
-28.14%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for STIM and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$55.3M
-15.2% YoY
FY Net Income
-$31.2M
+16.1% YoY
Free Cash Flow
-$30.3M
+10.8% YoY
Revenue Growth
+99.2%
EPS Growth
+57.2%
Gross Margin
48.5%
Net Margin
-26.1%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 149M | 75M | 71M | 65M | 55M |
| Gross Profit | 72M | 54M | 52M | 50M | 44M |
| Operating Income | -31M | -35M | -31M | -35M | -28M |
| EBITDA | -28M | -34M | -23M | -32M | -27M |
| Net Income | -39M | -44M | -30M | -37M | -31M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 34M | 19M | 60M | 70M | 94M |
| Total Assets | 142M | 141M | 116M | 117M | 141M |
| Total Liabilities | 115M | 109M | 82M | 60M | 56M |
| Shareholder Equity | 22M | 28M | 34M | 57M | 85M |
| Total Debt | 90M | 83M | 62M | 40M | 40M |
| Net Debt | 56M | 63M | 3M | -31M | -55M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
28M
+9.0% YoY
Capital Expenditures
2M
+28.0% YoY
Free Cash Flow
30M
+10.8% YoY
Key ratios
Gross Margin
48.5%
Operating Margin
-21.1%
Net Margin
-26.1%
ROE
-138.9%
Debt / Equity
4.04x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.